272.11 USD
+2.68
0.99%
At close Jan 17, 4:00 PM EST
After hours
272.11
+0.00
0.00%
1 day
0.99%
5 days
3.82%
1 month
2.32%
3 months
-15.32%
6 months
-18.94%
Year to date
4.95%
1 year
-10.51%
5 years
12.68%
10 years
72.66%
 

About: Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Employees: 26,700

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

76% more first-time investments, than exits

New positions opened: 172 | Existing positions closed: 98

1% more funds holding

Funds holding: 2,741 [Q2] → 2,774 (+33) [Q3]

2% more call options, than puts

Call options by funds: $2.67B | Put options by funds: $2.61B

2% less capital invested

Capital invested by funds: $134B [Q2] → $132B (-$2.83B) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 1,078 | Existing positions reduced: 1,120

3.6% less ownership

Funds ownership: 79.97% [Q2] → 76.38% (-3.6%) [Q3]

21% less funds holding in top 10

Funds holding in top 10: 87 [Q2] → 69 (-18) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$256
6%
downside
Avg. target
$330
21%
upside
High target
$405
49%
upside

10 analyst ratings

positive
50%
neutral
40%
negative
10%
Wells Fargo
Mohit Bansal
31% 1-year accuracy
8 / 26 met price target
3%upside
$280
Equal-Weight
Maintained
10 Jan 2025
Truist Securities
Robyn Karnauskas
11% 1-year accuracy
3 / 28 met price target
10%upside
$298
Hold
Maintained
8 Jan 2025
Piper Sandler
David Amsellem
58% 1-year accuracy
23 / 40 met price target
14%upside
$310
Overweight
Maintained
2 Jan 2025
B of A Securities
Tim Anderson
67% 1-year accuracy
4 / 6 met price target
6%downside
$256
Underperform
Reinstated
10 Dec 2024
RBC Capital
Gregory Renza
34% 1-year accuracy
29 / 86 met price target
21%upside
$330
Outperform
Maintained
27 Nov 2024

Financial journalist opinion

Based on 37 articles about AMGN published over the past 30 days

Positive
Zacks Investment Research
6 hours ago
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
Negative
Zacks Investment Research
2 days ago
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Amgen (AMGN) closed at $272.11, marking a +0.99% move from the previous day.
Amgen (AMGN) Rises Yet Lags Behind Market: Some Facts Worth Knowing
Neutral
PRNewsWire
3 days ago
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif. , Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Positive
Reuters
3 days ago
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients with a specific gene mutation.
US FDA approves Amgen's colorectal cancer therapy
Positive
The Motley Fool
4 days ago
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while -- is one of the best formulas for earning terrific returns.
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
Negative
Zacks Investment Research
5 days ago
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Amgen (AMGN) closed at $267.10, indicating a -1.14% shift from the previous trading day.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Positive
Zacks Investment Research
6 days ago
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
Positive
Zacks Investment Research
6 days ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Positive
The Motley Fool
6 days ago
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
A $5,000 investment can go a long way, especially if you're loading up on fairly cheap stocks that may possess a lot of upside in the long run. By investing $5,000, you can ensure that if you pick a great stock, your profits could be significant.
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Neutral
Seeking Alpha
6 days ago
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Amgen Inc. (NASDAQ:AMGN ) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 6:00 PM ET Company Participants Robert Bradway - Chairman, CEO & President Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody.
Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Charts implemented using Lightweight Charts™